Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 836

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 836
---
aid does not exceed Prof. Revel’s total investment in the public offering in any case. The Company has the right to an early repayment of the loan or part thereof without an early repayment penalty. Due to the aforementioned updates to the loan terms, in the years 2023 and 2022, the Company credited a benefit to the interested party transactions capital reserve, equal to USD $129 and $114 thousand, net. Note 10: — Trade payables

|                  |     |      December 31 |     |       |
|                  |     |             2023 |     |  2022 |
|                  |     | USD in thousands |     |       |
| Open accounts    |     |              133 |     |   649 |
| Accrued expenses |     |              399 |     |   400 |
|                  |     |              532 |     | 1,049 |

Note 11: — Accounts payable

|                                  |     |      December 31 |     |      |
|                                  |     |             2023 |     | 2022 |
|                                  |     | USD in thousands |     |      |
| Employees and payroll accruals*) |     |              226 |     |  362 |

____________ *)including a bonus in the amount of USD $82 thousand in respect of a liability to related parties (see Note 22).

Annex G-19

KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 12: — CONTINGENT liabilities to the Innovation Authority in respect of royalties A.The Company received grants from the government of Israel for participation in research and development, and in exchange, it had committed to pay royalties at a rate of 3% from sales of the research and development outcomes that were funded up to the total grants received, dollar -linkedand plus interest at the LIBOR interest (see Note 2c). B.On March 2, 2022, the Company received the approval of the IIA to receive a support grant for a total budget of USD $3 million (NIS 10 million) (hereinafter, the “Budget”), for the purpose of a plan to continue the development of cellular therapy to treat ALS. The IIA’s participation will be at a rate of 40% of the total Budget. As of the date of the financial statements, USD $797 were received. The total grants received from the National Authority for Technological Innovation by December 31